PRAECIS

26 May 2005

Dear Healthcare Provider:

IMPORTANT INFORMATION ABOUT PLENAXIS® AVAILABILITY

This letter is being sent to provide important information regarding the continued commercial use and availability of Plenaxis® (abarelix for injectable suspension). Our records indicate that you are enrolled in the Plenaxis® User Safety (PLUS) Program, and that you are therefore authorized to prescribe Plenaxis® for your patients.

As announced on May 20, 2005, as part of a strategic restructuring of its organization and operations, PRAECIS PHARMACEUTICALS INCORPORATED ("PRAECIS" or the "Company") has voluntarily discontinued promotional activities relating to Plenaxis® in the United States and the sale of Plenaxis® for patients not currently on therapy. This difficult decision was prompted solely by commercial considerations, and was not prompted in any way by safety, efficacy or other regulatory issues.

PRAECIS is working with the United States Food and Drug Administration to continue to make Plenaxis® available to those patients in the United States who are now receiving the drug and to minimize disruptions in these patients' therapy. Accordingly, until further notice, you may continue to treat patients currently receiving Plenaxis®, and, if necessary, you may order additional Plenaxis® kits for those patients through your established ordering channels. You must continue to abide by all of the terms of the Physician Attestation of Qualifications and Acceptance of Prescribing Responsibilities that you signed in connection with your enrollment in the PLUS Program. You should not utilize product in your inventory to initiate new patients on Plenaxis® therapy.

Any unused kits of Plenaxis® should be returned to the distributor from whom you made your purchase for a refund.

PRAECIS will inform you of any new or unexpected information regarding the use of Plenaxis® that may become available in a timely fashion. If you have any questions regarding the important information contained in this letter, please contact PRAECIS Medical Information at (781) 795-4303 or (866) PLENAXIS.

PRAECIS is committed to ensuring that patients currently receiving Plenaxis® continue to receive the benefit of treatment for as long as appropriate. The decision to cease making Plenaxis® available to new patients at this time was an extremely difficult one and one that was made after carefully weighing all alternatives. PRAECIS appreciates your understanding and will continue to work with you during this transition period.

Sincerely yours,

Marc B. Garnick, M.D.
Chief Medical and Regulatory Officer
PRAECIS PHARMACEUTICALS INCORPORATED

PL40 05/05

PRAECIS
PHARMACEUTICALS
INCORPORATED

830 Winter Street
Waltham, MA 02451-1420

Tel 781 795 4100
www.praecis.com